Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Upstream Bioprocessing Equipment Market Report 2026: Forecast to 2030 | Accelerate Single-Use Scale-Up as Thermo Fisher, Merck, Danaher, Sartorius and Repligen Drive 10.9% CAGR

globenewswire.com
TMO Thermo Fisher is mentioned as a key driver in the growing upstream bioprocessing equipment market, which is projected to expand significantly due to increased biopharmaceutical manufacturing and adoption of new technologies. MRK Merck is identified as a key player in the expanding upstream bioprocessing equipment market, benefiting from growth in biopharmaceutical manufacturing and the adoption of advanced technologies. DHR Danaher is highlighted as a significant contributor to the growth of the upstream bioprocessing equipment market, driven by increased biopharmaceutical production and technological advancements. RGEN Repligen's technology is integrated into a new system launched by Sartorius, highlighting its role in driving innovation and efficiency in the growing upstream bioprocessing equipment market.

Upstream Bioprocessing Equipment Market Report 2026: Forecast to 2030 | Accelerate Single-Use Scale-Up as Thermo Fisher, Merck, Danaher, Sartorius and Repligen Drive 10.9% CAGR Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Upstream Bioprocessing Equipment Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The global upstream bioprocessing equipment market is projected to grow rapidly as biopharmaceutical manufacturers expand production capacity and adopt more flexible, efficient manufacturing technologies. The market is expected to increase from $11.13 billion in 2025 to $12.32 billion in 2026, representing a compound annual growth rate (CAGR) of 10.6%.

Historical market growth has been supported by rising demand for monoclonal antibodies and vaccines, increased investment in biopharmaceutical manufacturing facilities, and wider adoption of mammalian cell culture systems. The expansion of contract manufacturing organizations has also contributed to demand for upstream bioprocessing equipment. At the same time, manufacturers have focused on improving process efficiency, increasing production yields, and maintaining consistent quality across development and commercial manufacturing operations.

The upstream bioprocessing equipment market is forecast to reach $18.61 billion by 2030, expanding at a CAGR of 10.9%. Growth during the forecast period is expected to be driven by a larger pipeline of biologics and biosimilars, rising demand for personalized medicines, and continued expansion of gene and cell therapy manufacturing. Investment in flexible biomanufacturing facilities and the increasing adoption of single-use technologies are also expected to support market development.

Key upstream bioprocessing equipment market trends include the growing use of single-use bioreactor systems, which can improve production flexibility and reduce contamination risks. Demand for perfusion-based cell culture systems is also increasing as manufacturers pursue continuous biologics production. Modular and scalable equipment is enabling companies to expand facilities more quickly, while closed-system bioprocessing solutions are helping enhance sterility and operational efficiency. Automated sampling, real-time monitoring, and advanced process control systems are becoming increasingly important for maintaining consistency throughout upstream production.

The need for scalable bioprocessing solutions is a major market growth driver. Rapid expansion of biologics development pipelines requires manufacturing platforms that can support multiple production volumes while maintaining product quality and process reliability. Advanced bioreactors, fermentation equipment, filtration technologies, and integrated upstream systems allow biopharmaceutical companies to move efficiently from research and process development to commercial-scale manufacturing.

Investment activity within the biotechnology sector further reinforces this demand. In January 2025, the BioIndustry Association reported that the UK biotechnology sector secured approximately $4.4 billion in investment, an increase of 94% compared with the previous year. Stronger investment can accelerate drug development, facility expansion, and the adoption of modern upstream bioprocessing equipment.

Product innovation remains central to market competition. In August 2023, Sartorius AG launched an integrated Biostat STR system incorporating Repligen's XCell Alternating Tangential Flow technology. The platform combines hardware and software modules, predefined control recipes, real-time process monitoring, and enhanced cell-retention capabilities. By reducing the need for separate control units, the system is designed to simplify upstream workflows and support high-density cell culture applications.

Strategic acquisitions are also reshaping the bioprocessing technology landscape. In May 2023, Getinge acquired High Purity New England, Inc. for $120 million, with an additional earn-out of up to $170 million. The acquisition expanded Getinge's single-use solutions portfolio and strengthened its capabilities across upstream and downstream bioprocessing applications, including equipment used in drug discovery and biopharmaceutical manufacturing.

North America was the largest region in the upstream bioprocessing equipment market in 2025, while Asia-Pacific is expected to record the fastest growth during the forecast period. The market spans Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain.

Markets Covered:

1) By Product Type: Bioreactors And Fermenters; Cell Culture Vessels; Filtration Systems; Mixing Systems; Sampling Systems; Other Product Types

2) By Workflow: Media Preparation; Cell Culture; Cell Separation

3) By Application: Monoclonal Antibodies Production; Vaccines Manufacturing; Recombinant Proteins; Gene Therapy; Other Application

4) By End User: Pharmaceutical And Biotechnology Companies; Contract Manufacturing Organizations; Academic And Research Institutes

Subsegments:

1) By Bioreactors And Fermenters: Stirred Tank Bioreactors; Airlift Bioreactors; Bubble Column Bioreactors; Wave Induced Bioreactors; Packed Bed Bioreactors; Fluidized Bed Bioreactors

2) By Cell Culture Vessels: Cell Culture Flasks; Cell Culture Plates; Cell Culture Bottles; Spinner Flasks; Roller Bottles; Cell Culture Bags

3) By Filtration Systems: Depth Filtration Systems; Microfiltration Systems; Ultrafiltration Systems; Nanofiltration Systems; Membrane Filtration Systems; Cross Flow Filtration Systems

4) By Mixing Systems: Magnetic Mixing Systems; Mechanical Mixing Systems; Static Mixing Systems; Single Use Mixing Systems; High Shear Mixing Systems; Low Shear Mixing Systems

5) By Sampling Systems: Manual Sampling Systems; Automated Sampling Systems; Aseptic Sampling Systems; In Line Sampling Systems; Off Line Sampling Systems; Closed Sampling Systems

6) By Other Product Types: Incubators; Centrifuges; Sensors And Probes; Sterilization Equipment; Media Preparation Systems; Single Use Assemblies

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Key Attributes

The companies featured in this Upstream Bioprocessing Equipment market report include:

For more information about this report visit https://www.researchandmarkets.com/r/lwn7o3

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.